FRANKFURT, Germany (AP) — Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.
Core net income fell 2 percent to $2.94 billion from $2.99 billion in the previous-year quarter. The loss of Gleevec, used to treat chronic myeloid leukemia, to generic use hurt sales revenue.
Gilenya, a medicine for relapsing multiple sclerosis, brought in $790 million, an increase of 15 percent.
The company said that Cosentyx, with $301 million in sales, was “on track for blockbuster status” in its first full year after approval.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
